ey0015.12-14 | Important for clinical practice (1) | ESPEYB15
RP Giugliano
, F Mach
, K Zavitz
, C Kurtz
, K Im
, E Kanevsky
, J Schneider
, H Wang
, A Keech
, TR Pedersen
, MS Sabatine
, PS Sever
, JG Robinson
, N Honarpour
, SM Wasserman
, BR Ott
, EBBINGHAUS Investigators
To read the full abstract: N Engl J Med 2017;377:633-643Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates levels of plasma LDL-C by interacting with the LDL receptor. After binding and internalization, PCSK9 directs the LDL receptor to lysosomal degradation and inhibits its recycling to the cell surface, and thus accelerates the degradation of hepatic LDL receptors. This reduces the ...